Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Q3 2021 Syndax Pharmaceuticals Inc Earnings Call Transcript

Nov 15, 2021 / 09:30PM GMT
Release Date Price: $17.89 (-0.17%)
Operator

Good day, and thank you for standing by. Welcome to the Syndax Third Quarter 2021 Conference Call. (Operator Instructions). I would now like to hand the conference over to your first speaker today, Melissa Forst with Argot Partners. Thank you and please go ahead.

Melissa Forst
Argot Partners, LLC - SVP

Thank you, operator. Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for view of Syndax's third quarter 2021 financial and operating results. With me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Michael Metzger, President and Chief Operating Officer.

Also joining us on the call today for the question-and-answer session is Dr. Michael Meyers, Chief Medical Officer; Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Business Officer. This call is being accompanied by a slide deck that has been posted on the company's website. So I would ask that you please turn to the forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot